Oncology Central

‘Et tu, inhibitor?’: the potential for HIV inhibitors to prime P-gp-mediated chemoresistance in cancer

0
The major hurdle regarding effective cancer treatment is the ability to prevent and overcome the mechanisms that drive chemoresistance. It is through chemoresistance that tumor populations are given opportunity to acquire more aggressive, metastatic phenotypes and decrease the chances of overall survival in patients carrying the pathophysiological burden of chemoresistant tumors. Based on this foundational issue regarding chemoresistance and cancer severity, efforts within the research community have been directed toward elucidating the molecular mechanisms that facilitate chemoresistance, many of which work in concert with one another.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.